In GSK Challenge Of Salonpas Claims, NAD Embarks On Review Of Unchartered Argument
'Regulatory Review’ Claim For Salonpas Not A Comparison To Voltaren Approval
Executive Summary
Hisamitsu America’s severity of pain claims for Salonpas challenged by GSK are more nuanced than what label indications support, but touting its regulatory approval doesn’t convey a message that other products aren’t subject to as rigorous pre-market evaluations.